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Abstract
Background: Periostin, an extracellular matrix protein, plays a significant role in adverse cardiac remodeling.
However, no report has documented the function of periostin in left ventricular remodeling of streptozototin
(STZ)-induced diabetic rats. The aim of the present study was to observe the expression of periostin in Wistar rat’s
myocardium of diabetic cardiomyopathy (DCM) and the effect of valsartan on it.
Methods: Immunohistochemistry, real-time polymerase chain reaction, and Western blot analysis were used to
determine the degree of expression and location of periostin, transforming growth factor (TGF)-β1, TGF-β1 type II
receptor (TGF-β1 R II), and Type I and III collagens in the myocardium of STZ-induced diabetic rats.
Results: Periostin, TGF-β1, TGF-β1 R II, and Type I and III collagens were significantly increased in the myocardium of
diabetic rats compared with control group on both messenger ribonucleic acid and protein levels. In addition, diabetic
rats treated with valsartan could have reduced expression of periostin and improved cardiac remodeling of DCM.
Conclusions: Periostin may play a crucial role in cardiac remodeling and myocardial interstitial fibrosis process of DCM
and it could be one of the important mechanisms for valsartan to improve the ventricular remodeling of DCM.
Background
Diabetes mellitus remains a highly prevalent and a vigor-
ous independent risk factor for cardiovascular disease.
Recently, an accumulating number of evidence has dem-
onstrated that the presence of abnormal myocardial
structure and myocardial dysfunction in patients with
diabetes in the absence of epicardial coronary artery dis-
ease (CAD), hypertension, and congestive heart failure
after adjusting left ventricular hypertrophy [1–3]. This
hypothesis was originally recognized in 1972 by Rubler
S, who described data from patients with diabetes and
heart failure without any evidence of CAD, valvular
heart disease, hypertension, or congenital heart disease.
This phenomenon has led to the increased recognition
of a distinct disease process defined as “diabetic cardio-
myopathy” (DCM). Multifactorial mechanisms were
thought to be involved in the pathogenesis of DCM. Pre-
dominantly, myocardial fibrosis and myocyte hypertrophy
are the significant mechanisms to explain the cardiac
changes of DCM [4].
Periostin, a 90-KDa secretory protein within the extra-
cellular matrix (ECM), has been derived from studies of
bone development wherein it is expressed in both the
periodontal ligament and the cortical bone periosteum
of adult mice [5]. The association between periostin and
myocardium was first reported in the context of mature
valves and endocardial cushion development [6]. Re-
cently, numerous studies have described a strong rela-
tionship between periostin overexpression and cardiac
remodeling in human [7] and rat failing heart or myo-
cardial heart [8–11]. Significantly, periostin is sensitive
to transforming growth factor (TGF)-β activation and
has emerged to play an important role in collagen fibril-
logenesis [12–14]. All of these findings suggest that peri-
ostin is an important novel factor in the pathogenesis of
cardiovascular disease and in the evolution of cardiac re-
modeling. Meanwhile in vitro study showed that high
glucose increased periostin expression in adult rat car-
diac fibroblasts [15]. So it is valuable to elucidate the ex-
pression level and possible function of periostin in
DCM.
Valsartan, an Angiotensin II (Ang II) receptor blocker,
has been reported to protect against diabetic cardiomy-
opathy [16]. Blockage of Ang II AT1 receptor is thought
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to be the main mechanism of valsartan’s protection on
cardiac remodeling. But is there any other mechanism
involved? In previous studies, it has been demonstrated the
existence and activation of a cardiac renin-angiostensin sys-
tem (RAS) in the hearts in diabetes [17]. Ang II could
stimulate the periostin expression in both fibroblasts and
cardiac myocytes in vitro, and this increase was inhibited
partially, but significantly, by valsartan [11, 18]. Periostin
can induce fibroblast proliferation and myofibroblast per-
sistence in vitro [19]. In vivo, valsartan can also signifi-
cantly attenuate the increased periostin expression,
accompanied by improvement of cardiac dysfunction in
acute myocardial infarction rat models [11]. But
whether periostin takes part in the valsartan-induced
protection of DCM is still unknown.
So it is worth clarifying the role of periostin in cardiac
remodeling of DCM as no studies yet documented the
relation between the periostin and DCM. In the present
study, the changes of periostin expressions in cardiac re-
modeling of DCM and the effects of valsartan on the
regulation of periostin expression were examined.
Methods
Induction of diabetes
Male healthy Wister-Albino rats (6-week-old; 180-
220 g; n = 60) were purchased from the animal center
of Lu-kang corporation. All experimental procedures
were performed in accordance with the institutional
animal care guidelines. Rats were housed in an air-
conditioned room at a constant temperature of 20 ± 2 °C
and were fed with a standard diet and water at liberty. Fol-
lowing one week of acclimatization, the rats were assigned
randomly to a control group (n = 10) and a diabetic group
(n = 50). All rats were weighed, then blood glucose levels
were measured initially before the experiment and then
weekly once throughout the experiment. Diabetes was in-
duced by a single intraperitoneal injection of streptozoto-
cin (STZ) (60 mg/kg body weight; Sigma, USA) dissolved
in 0.1 mmol/L sodium citrate buffer (pH adjusted to 4.2),
whereas rats in control group were injected with
0.1 mmol/L citrate buffer alone. All rats were given the
same weight of normal (non-high fat and sugar) diet and
the same volume of water. Three weeks after the injec-
tion of STZ, blood was collected from tail vein and
samples were analyzed for blood glucose using a gluc-
ometer. Rats with random fasting blood glucose levels
greater than 16.7 mmol/L were considered as the dis-
tribution criteria of type 1 diabetic rat. In addition,
the eligible diabetic rats were randomly assigned to
two groups: diabetes group (n = 21) and diabetes plus
valsartan group (n = 20). Rats in diabetes plus valsar-
tan group were given valsartan by gavage using a suit-
able intubation cannula at 30 mg/kg/day dose levels
to soluble in 5 mL distilled water, whereas rats in the
diabetes group were administered with the same
amount of distilled water each day. No additional
treatments were given to control rats.
After 16 weeks, all animals from each group were eutha-
nized using pentobarbital and fresh hearts were harvested
immediately. Then, weight of the left ventricle was noted in
order to observe the degree of left ventricular hypertrophy.
Furthermore, a transversal cross-section block was cut from
the left ventricle, soaked in 4 % paraformaldehyde, and
remained frozen in liquid nitrogen until mechanical testing.
Hematoxylin eosin (HE) and Masson’s trichrome stain of
myocardial tissue
After 48 h of treatment with 4 % paraformaldehyde, the
tissues were dehydrated and the transparent tissues were
embedded in paraffin. The tissues were cut into 6-μm
slices, heated at 60 °C for 3 h, dewaxed, and stained with
HE and Masson’s trichrome dyeing kits. Each slice was
analyzed under a microscope at 400× magnification. The
collagen volume fraction was determined as the ratio of
interstitial collagen area to myocardial area.
Immunohistochemistry
For immunohistochemical analysis, the transversal sec-
tions of the left ventricle were cut into 5-μm sections
and the endogenous peroxidase activity was quenched
by incubation with 3 % hydrogen peroxide for 15 min.
The sections were then blocked using 5 % bovine serum
albumin to prevent the nonspecific staining with the sec-
ondary antibodies. After overnight incubation at 4 °C with
primary antibodies (anti-periostin, anti-TGF-β1, anti-
TGF-β1 RII, and anti-collagen I and III antibodies were
used at 1:100 dilutions), the sections were exposed to the
secondary antibody conjugated with horseradish peroxid-
ase. The reaction was visualized using a light microscopy
with 3, 3’-diamno-benzidine tetrahydrochloride.
Western blot analysis
Protein fractions were isolated in ice-cold radioimmu-
noprecipitation assay lysis buffer (Beyotime, China) and
protein concentrations were determined using the en-
hanced bicinchoninic acid protein assay kit (Beyotime,
China). Protein fractions were denatured in a loading buf-
fer, and 100 μg of each sample was loaded into alternating
lane of 10 % sodium dodecyl sulfate -polyacrylamide gel.
Protein blots were transferred to polyvinylidene fluoride
membranes (Milipore, USA). After blocking with 5 %
non-fat milk, the blots were washed with a mixture of
Tris-buffered saline and Tween 20 (TBST) and incubated
overnight at 4 °C with an appropriate primary antibody
(anti-β-actin, anti-periostin, anti-TGF-β1, anti-TGF-β1 II
R, and anti-collagen I and III antibodies were used at
1:1000, 1:500, 1:400, 1:2000, 1:2000, and 1:5000 dilutions,
respectively). Membranes were washed with TBST and
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then incubated at room temperature for 1 h with an ap-
propriate secondary antibody conjugated to horseradish
peroxidase and washed again. Finally, the protein blots
were visualized using an enhanced chemiluminescence kit
(Millipore, USA). Relative intensities of protein bands
were measured using Gel-Pro analyzer. β-actin was used
as a control.
Real-time polymerase chain reaction (RT-PCR) analysis
The total RNA was extracted from the frozen myocardial
tissues using Trizol reagent (Invitrogen, USA), according
to the manufacturer’s instructions. The concentration of
extracted total RNA was quantified using spectrophotom-
etry. The reverse transcription of RNA to complementary
deoxyribonucleic acid (cDNA) was performed using Sensi-
script RT kit (TaKaRa Biotechnology, China). Total cDNA
was amplified with LightCycler-FastStart DNA Master
SYBR Green I (TaKaRa Biotechnology, China). Primers
for rats periostin, TGF-β1, TGF-β1 R II, Type I collagen,
Type III collagen, and β-actin were designed by TaKaRa
Biotechnology Corporation: Periostin S: 5’-GGCTGAAGA
CTGCCTTGAATGAC-3’, A: 5’-CGTGGCAGCACCTTC
AAAGA-3’; TGF-β1 S: 5’-AGGTAACGCCAGGAATTGT
TGCTA-3’, A: 5’-CATTGCTGTCCCGTGCAGA-3’; TGF-
β1 R II S: 5’-CTACAAGGCCAAGCTGAAGC-3’, A: 5’-A
GCCAATGGAAGTAGACATCCG-3’; collagen I S: 5’-AG
GGACCCTTAGGCCATTGTGTA-3’, A: 5’-GACATGTT
CAGCTTTGTGGACCTC-3’; collagen III S: 5’-GACAG
ATCCCGAGTCGCAGA-3’, A: 5’-TTTGGCACAGCAGT
CCAATGTA-3’; and β-actin S: 5’-AGACCTTCAACACC
CCAG-3’, A: 5’-CACGATTTCCCTCTCAGC-3’. Amplifi-
cation process included an initial denaturation step of 30s
at 95 °C followed by 40 cycles of three-step procedure (de-
naturation at 95 °C for 5 s, annealing at 60 °C for 30s, and
extension at 60 °C for 30s) and then a melting-curve pro-
cedure at 60 °C for 1 min. At the end of each cycle, fluor-
escence emitted by the SYBR Green I dye was measured.
For each PCR product, a single narrow peak was obtained
through melting curve analysis at a specific melting-curve
temperature, indicating specific amplifications. The
amount of periostin, TGF-β1, TGF-β1 R II, Type I and
Type III collagens, and β-actin transcripts was calculated
from their respective standard curves using the Light Cy-
cler software. Samples were tested for three times, and
the average values were used for quantification. Ul-
timately, the relative expression levels of each target
gene were normalized to the messenger RNA (mRNA)
of the internal standard gene β-actin.
Statistical analysis
All data were expressed as mean ± standard error of the
mean. Comparisons between two groups were per-
formed using paired student’s t test. One-way analysis of
variance was used to compare more than two groups. A
value of P less than 0.05 was considered statistically
significant.
Results and discussion
General characteristics of the experimental rats
At the end of the experiment, 21 STZ-induced diabetic
rats, 20 diabetic rats with valsartan, and 10 control rats
were survived, and the rest of 9 diabetic rats were died
due to infection. Blood glucose levels were significantly
increased in diabetic rats compared with control rats at
the end of one week after STZ injection, the difference
has statistically significant (p = 0.0002). Meanwhile, the
glucose levels of diabetic rats were decreased by valsar-
tan treatment at the end of nine weeks, the difference
between diabetic group and diabetic plus valsartan have
statistically significant (p = 0.0197) (see Fig. 1). The STZ-
induced diabetic rats were at a diabetic state of polydip-
sia, polyphagia, and polyuria with lowered body weights.
Degree of left ventricular hypertrophy
Left ventricular coefficient, used to assess the extent of
cardiac hypertrophy, which can calculated by compar-
ing the left ventricular weight and body weight [20].
The left ventricular coefficient of diabetic rats was
higher than control rats (p = 0.003), whereas it was
lower in the valsartan-treated diabetic rats than the dia-
betic rats without valsartan (p = 0.006), those differ-
ences have statistically significant (see Fig. 2).
Fig. 1 Serum glucose levels of experimental animals. The first week:
control (7.513 ± 1.589) vs DCM (26.534 ± 0.684) #p = 0.0002. The third
week: control (7.085 ± 0.527) vs DCM (25.940 ± 0.661) #p = 0.0001.
The sixth week: control (7.703 ± 0.454) vs DCM (28.811 ± 0.448)
#p = 0.0001. The ninth week: control (9.282 ± 0.167) vs DCM
(29.441 ± 0.406) vs valsartan (27.303 ± 0.398) #p = 0.0001,*p = 0.0197.
The twelfth week: control (7.948 ± 0.242) vs DCM (29.129 ± 0.591) vs
valsartan (26.887 ± 0.832) #p = 0.0001, *p = 0.0332. The fifteenth week:
control (8.949 ± 0.579) vs DCM (29.101 ± 0.599) vs valsartan (26.554 ±
0.542) #p = 0.0001, *p = 0.0347
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HE and Masson’s stains of myocardium
Through light microscope, it was observed that the dia-
betic rats had increased sizes as well as disordered ar-
rangement of cardiocytes compared with control rats,
while the myocardial distribution of valsartan-treated
group obviously improved than DCM group. The car-
diac collagen deposition was dramatically increased in
the diabetic rats than control rats. However, the amount
of collagen in valsartan-treated rats was markedly allevi-
ated than diabetic rats (see Fig. 3).
Immunohistochemical analysis
Immunohistochemical analysis revealed that the en-
hanced staining of periostin occurred in fibroblast,
endothelial cells, inflammatory cells, and myocytes in
hearts of diabetic rats, whereas little periostin protein
expression was found in the control rats. Similarly,
weak collagen I and III protein expressions were found in
the control rats, whereas the diabetic rats showed strong
collagen deposition in hearts. Furthermore, strong TGF-
β1 and TGF-β1 R II expressions were also obviously
found in diabetic rats; however, there was little or no
expression in the control rats. Moreover, in valsartan-
treated diabetic group, the expression of periostin,
TGF-β1, TGF-β1 R II, and Type I and III collagens
were alleviated compared to DCM group (see Fig. 4).
Western blot analysis
The present study results revealed that the expression of
periostin was extremely upregulated in DCM rats com-
pared to control rats. And the overexpression of perios-
tin was inhibited by the valsartan treatment. In addition,
TGF-β1, TGF-β1 R II, and Type I and III collagens were
regarded as a marker reflecting the activation of cardiac
fibrosis [21, 22]. All these markers were expressed
abundantly in the hearts of diabetic rats compared with
control rats, and all these marker expressions were re-
duced after the valsartan treatment (see Fig. 5).
Myocardial mRNA expression
The RT-PCR analysis revealed that a remarkable increase
in periostin mRNA expression in the diabetic rats com-
pared with control rats. In addition, the mRNA expres-
sions in valsartan-treated rats were significantly decreased
compared to diabetic rats after 8 weeks. Furthermore,
TGF-β1, TGF-β1 R II, and Type I and III collagen mRNA
expressions in DCM group were significantly increased
compared with control rats. While in valsartan-treated
group, the mRNA expressions were decreased compared
to the DCM group (see Fig. 6).
Conclusions
The DCM is associated with a significant myocardial
remodeling which consists of cardiac hypertrophy,
interstitial fibrosis, and changes in the cardiac metabol-
ism [23]. Abundant evidences from experimental
models of DCM indicated that the cardiac interstitial fi-
brosis and cardiac hypertrophy were the pathological
substrate features of DCM [24, 25]. In the present
study, Wister rats were made severely and chronically
diabetic for 16 weeks with a single intraperitoneal injec-
tion of STZ (60 mg/kg body weight), and at the end of
three weeks after STZ injection, the diabetic group rats
were at a state of hyperglycemic, unfortunately, eight
rats in diabetic group were died due to diabetic ketoaci-
dosis, infection, fighting each other or digestive compli-
cations. In addition, there was one rat, which blood
glucose does not meet the model standard, removed.
Therefore, preventing acidosis caused by high blood
sugar, keeping the environment clean and treating in-
fections as well as other complications to ensure the
quality and quantity of rats is very significant in this
kind of trials. Moreover, changes in the cellular morph-
ology and structural abnormalities of myocardium were
found in the experiment. From HE and Masson’s staining
of myocardium, it was found that the cardiomyocytes
were disorganized with abundant myocardial collagen de-
position, accompanied by a markedly increased left ven-
tricular mass index. These salient endings of the present
study demonstrated that 16 weeks of hyperglycemia
contributes to a successful experimental Type 1 DCM
with the development of cardiac hypertrophy and
fibrosis.
Previous studies had demonstrated the pathophysio-
logical role of periostin in myocardial fibrosis and car-
diac remodeling in vivo and in vitro. Oka T, et al [26]
found mice lacking the gene encoding periostin showed
less fibrosis and better ventricular performance after a
myocardial infarction, while inducible overexpression of
Fig. 2 The degree of left ventricular hypertrophy of experimental
animals. Control (1.43 ± 0.08) vs DCM (1.81 ± 0.8) vs valsartan
(1.52 ± 0.55) #p = 0.0295, *p = 0.0427
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periostin in the heart induced spontaneous hypertrophy
with aging. In both animal and human models, perios-
tin is closely associated with pressure overload-induced
left ventricular hypertrophy (LVH) and LVH regression
[9]. In vitro study found periostin is a profibrogenic matri-
cellular protein that promotes collagen fibrogenesis, inhibits
differentiation of progenitor cells into cardiomyocytes [27].
Periostin can also induce fibroblast proliferation and myofi-
broblast persistence in vitro [28]. In the present study, a
high level of mRNA and protein expressions of peri-
ostin was found in the hearts of diabetic rats, consist-
ent with the study of Zou P [15]. Periostin expression
Fig. 3 Hematoxylin and eosin stained (purple and red) rat’s myocardium. The cardiomyocytes size and quantity were increased in DCM rats
compared with control rats, whereas it was obviously alleviated in the valsartan-treated diabetic rats than DCM rats (×400). Masson’s trichrome
staining of rat’s myocardium revealed that the collagen deposition was obviously enhanced in the myocardium of diabetic rats than control rats;
however, the myocardial fibrosis was markedly decreased in the valsartan-treated rats than DCM rats (×400)
Fig. 4 Immunohistochemical staining of periostin, TGF-β1, TGF-β1 R II, and Type I and III collagens in the control, DCM, and valsartan-treated
group. The representative images of brown grain deposition showed the localization of the proteins. In contrast to the little or no protein staining
in the control rat’s myocardium, the DCM rats displayed increased expression of above mentioned proteins in the heart, while the protein
expressions were decreased in the valsartan-treated diabetic rats comparted to DCM group (×200)
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is localized to fibroblast, endothelial cells, inflamma-
tory cells, and myocytes of the damaged heart. These
results suggest that periostin might play an important
role in the pathogenesis of DCM. Furthermore, in the
DCM process, its myocardial cells metabolic disorders
include glucose metabolism and lipid metabolism. The
carbohydrate oxidation for energy is reduced and the
use of lipid oxidation is increased as well as the mater-
ial for the energy transferred from glucose to fatty
acids, so the free fatty acid is elevated caused by lipid
metabolism disorders has been widely accepted [29]. In
addition, Carley et al [30] have shown that fatty acid, the
endogenous ligand of Peroxisome Proliferator Activated
Receptors α (PPARα), which uptake and utilization in the
regulation of PPARα. Morever, the energy metabolism
signaling pathway of PPARα-FFA in cardiomyocytes may
joint with ventricular remodeling, which are important
reasons for the pathogenesis of diabetic cardiomyopathy
[31]. More study is needed to demonstrate if there is any
relationship between FFA-metabolism and periostin on
diabetic cardiomyopathy.
Experiment has demonstrated the existence and ac-
tivation of a cardiac rennin-angiostensin system (RAS)
in the hearts in diabetes [17]. In diabetic hearts, both
the density and mRNA levels of Ang II receptors are
increased [32, 33]. Blockage of RAS by Ang II receptor
(AT1R) blockers prevents diabetes-induced heart dys-
function [34]. In our study, varstan, an AT1R antagon-
ist, not only alleviated cardiac remodeling in DCM,
but also reduced periostin expression. Together with
Fig. 5 Western blot analysis of periostin (A), TGF-β1 (B), TGF-β1 R II (C), Type I (D) and III collagen (E) proteins expression in the hearts of
control rats, valsartan-treated rats, and DCM rats. (a) The representative Western blot images demonstrated these protein expression levels
in three groups. (b) Graph demonstrating quantification of these proteins in Western blot. DCM group showed obviously enhanced
proteins expression of periostin, TGF-β1, TGF-β1 R II, Type I and III collagen in hearts compared to control rats. The expression of proteins
was significantly alleviated in the valsartan-treated group than DCM group. Data were shown as mean ± SEM. #P < 0.05 vs. control;
*P < 0.05 vs. DCM
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the knowledge that Ang II could promote the mRNA
and protein expression of periostin in vivo and in
vitro [11], and periostin has been proved to take part
in cardiac remodeling, we can conclude that valsartan
could attenuate the cardiac remodeling in the DCM
rats partly via down-regulating the expression of peri-
ostin. Periostin may become a new therapeutic target
for DCM.
In addition, the present study data also revealed
that the blood glucose levels of valsartan-treated dia-
betic rats were improved compared with diabetic rats.
This result was accordant with the study of Chan P
et al [35], which indicated that valsartan, not only de-
creased the systolic blood pressure but also improved
the glucose utilization.
In conclusion, the present study findings confirmed
up-regulated expression of periostin in DCM and pro-
vided strong evidence that valsartan protects against
the cardiac remodeling in DCM rats which may partly
related to the down-regulation of periostin protein,
and provides a new insight into the potential thera-
peutic strategy of cardiac remodeling in DCM.
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